Royal Bank Of Canada reissued their outperform rating on shares of Aptose Biosciences Inc (TSE:APS) in a research report report published on Tuesday, StockTargetPrices.com reports.
Separately, Roth Capital increased their target price on shares of Aptose Biosciences from C$4.00 to C$8.00 and gave the company a buy rating in a report on Monday, June 13th.
Aptose Biosciences (TSE:APS) opened at 2.88 on Tuesday. Aptose Biosciences has a 12-month low of $2.51 and a 12-month high of $8.33. The firm’s market cap is $37.13 million. The company has a 50-day moving average of $2.89 and a 200 day moving average of $3.29.
Aptose Biosciences Company Profile
Aptose Biosciences Inc (Aptose) is a clinical-stage biotechnology company. The Company is engaged in the development of anticancer drugs that target specific epigenetic processes and signal transduction abnormalities that underlie a particular life-threatening malignancy. Its product pipeline includes cancer drug candidates that exert activity as stand-alone agents and that enhance the activities of other anticancer agents without causing overlapping toxicities.
Receive News & Ratings for Aptose Biosciences Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences Inc and related companies with MarketBeat.com's FREE daily email newsletter.